Nanotechnology-integrated ovarian cancer metastasis therapy: Insights from the metastatic mechanisms into administration routes and therapy strategies

被引:7
作者
Huang, Yu [1 ]
Li, Chaoqun [2 ]
Zhang, Xiao [2 ]
Zhang, Meng [2 ]
Ma, Yidan [3 ]
Qin, Dongxu [2 ]
Fei, Weidong [2 ]
Qin, Jiale [2 ]
机构
[1] Zhejiang Chinese Med Univ, Acad Chinese Med Sci, Hangzhou 310053, Peoples R China
[2] Zhejiang Univ, Womens Hosp, Sch Med, Hangzhou 310006, Peoples R China
[3] Yipeng Med Care Ctr, Dept Pharm, Hangzhou 311225, Peoples R China
基金
中国国家自然科学基金;
关键词
Ovarian cancer; Nanotechnology; Metastatic mechanism; Administration routes; Treatment; GYNECOLOGIC-ONCOLOGY-GROUP; HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY; EPITHELIAL-MESENCHYMAL TRANSITION; STEM-CELLS; E-CADHERIN; LYSOPHOSPHATIDIC ACID; PHASE-I; PERITONEAL CARCINOMATOSIS; DEBULKING SURGERY; PACLITAXEL;
D O I
10.1016/j.ijpharm.2023.122827
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Ovarian cancer is a kind of malignant tumour which locates in the pelvic cavity without typical clinical symp-toms in the early stages. Most patients are diagnosed in the late stage while about 60 % of them have suffered from the cancer cells spreading in the abdominal cavity. The high recurrence rate and mortality seriously damage the reproductive needs and health of women. Although recent advances in therapeutic regimes and other adjuvant therapies improved the overall survival of ovarian cancer, overcoming metastasis has still been a challenge and is necessary for achieving cure of ovarian cancer. To present potential targets and new strategies for curbing the occurrence of ovarian metastasis and the treatment of ovarian cancer after metastasis, the first section of this paper explained the metastatic mechanisms of ovarian cancer comprehensively. Nanomedicine, not limited to drug delivery, offers opportunities for metastatic ovarian cancer therapy. The second section of this paper emphasized the advantages of various administration routes of nanodrugs in metastatic ovarian cancer therapy. Furthermore, the third section of this paper focused on advances in nanotechnology-integrated stra-tegies for targeting metastatic ovarian cancer based on the metastatic mechanisms of ovarian cancer. Finally, the challenges and prospects of nanotherapeutics for ovarian cancer metastasis therapy were evaluated. In general, the greatest emphasis on using nanotechnology-based strategies provides avenues for improving metastatic ovarian cancer outcomes in the future.
引用
收藏
页数:17
相关论文
共 162 条
[1]   Lipid homeostasis and regulated cell death [J].
Agmon, Eran ;
Stockwell, Brent R. .
CURRENT OPINION IN CHEMICAL BIOLOGY, 2017, 39 :83-89
[2]   Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer [J].
Alberts, DS ;
Liu, PY ;
Hannigan, EV ;
OToole, R ;
Williams, SD ;
Young, JA ;
Franklin, EW ;
ClarkePearson, DL ;
Malviya, VK ;
DuBeshter, B ;
Adelson, MD ;
Hoskins, WJ .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 335 (26) :1950-1955
[3]   Surface-enhanced Resonance Raman Scattering Nanoprobe Ratiometry for Detecting Microscopic Ovarian Cancer via Folate Receptor Targeting [J].
Andreou, Chrysafis ;
Oseledchyk, Anton ;
Nicolson, Fay ;
Berisha, Naxhije ;
Pal, Suchetan ;
Kircher, Moritz F. .
JOVE-JOURNAL OF VISUALIZED EXPERIMENTS, 2019, (145)
[4]   Phase I study of weekly paclitaxel and liposomal doxorubicin in patients with advanced solid tumours [J].
Androulakis, N ;
Kouroussis, C ;
Mavroudis, D ;
Kakolyris, S ;
Souglakos, J ;
Agelaki, S ;
Kalbakis, K ;
Malas, K ;
Pallis, A ;
Samonis, G ;
Georgoulias, V .
EUROPEAN JOURNAL OF CANCER, 2002, 38 (15) :1992-1997
[5]   Pharmacokinetics of concomitant cisplatin and paclitaxel administered by hyperthermic intraperitoneal chemotherapy to patients with peritoneal carcinomatosis from epithelial ovarian cancer [J].
Ansaloni, L. ;
Coccolini, F. ;
Morosi, L. ;
Ballerini, A. ;
Ceresoli, M. ;
Grosso, G. ;
Bertoli, P. ;
Busci, L. M. ;
Lotti, M. ;
Cambria, F. ;
Pisano, M. ;
Rossetti, D. ;
Frigerio, L. ;
D'Incalci, M. ;
Zucchetti, M. .
BRITISH JOURNAL OF CANCER, 2015, 112 (02) :306-312
[6]   Intraperitoneal cisplatin and paclitaxel in ovarian cancer [J].
Armstrong, DK ;
Bundy, B ;
Wenzel, L ;
Huang, HQ ;
Baergen, R ;
Lele, S ;
Copeland, LJ ;
Walker, JL ;
Burger, RA .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (01) :34-43
[7]   Adding Nanotechnology to the Metastasis Treatment Arsenal [J].
Banerjee, Debarshi ;
Cieslar-Pobuda, Artur ;
Zhu, Geyunjian Harry ;
Wiechec, Emilia ;
Patra, Hirak K. .
TRENDS IN PHARMACOLOGICAL SCIENCES, 2019, 40 (06) :403-418
[8]   Motility-Driven Glass and Jamming Transitions in Biological Tissues [J].
Bi, Dapeng ;
Yang, Xingbo ;
Marchetti, M. Cristina ;
Manning, M. Lisa .
PHYSICAL REVIEW X, 2016, 6 (02)
[9]   Lysophosphatidic acid stimulates ovarian cancer cell migration via a Ras-MEK kinase 1 pathway [J].
Bian, DF ;
Su, SB ;
Mahanivong, C ;
Cheng, RK ;
Han, QW ;
Pan, ZXK ;
Sun, PQ ;
Huang, S .
CANCER RESEARCH, 2004, 64 (12) :4209-4217
[10]   Endothelium and cancer metastasis: Perspectives for antimetastatic therapy [J].
Blazejczyk, Agnieszka ;
Papiernik, Diana ;
Porshneva, Kseniia ;
Sadowska, Joanna ;
Wietrzyk, Joanna .
PHARMACOLOGICAL REPORTS, 2015, 67 (04) :711-718